The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
HOME > ORGANIZATION
ORGANIZATION
- Products Re-Priced Due to Market Expansion Should Be Eligible for New Drug Premium to Promote Innovation: FPMAJ
June 12, 2012
- FPMAJ’s Subcommittee Calls for Discussion on Need for “Ad Hoc Price Reduction” for Long-Listed Drugs
June 12, 2012
- FPMAJ’s NHI Drug Price Study Committee to Set Up Task Forces for Long-Listed Products, Cost Effectiveness
June 11, 2012
- Chairman Kamoya of FPMAJ’s Committee on NHI Drug Pricing Expresses Concern Over Long-Listed Drugs
June 11, 2012
- JAPMS to Establish Working Group on Improvement of Drug Distribution
June 6, 2012
- JMA Board Members Caution Against Rush to Introduce Cost-Effective Assessment: Dr Suzuki
June 5, 2012
- MREAC to Release Passing Scores for MR Exam Starting This Year
June 4, 2012
- JMA Requests FPMAJ, JPMA to Set Up Nursery Care Facilities for Lectures
June 4, 2012
- Head of Wholesale Industry FTC Calls for Compliance with Competition Code as Violation Cases Increase to Five
May 29, 2012
- Capital Investment Needed for Bar Code Labeling Estimated at About 700 Million Yen Per Drug Maker: JPWA, JPMA Survey
May 28, 2012
- Three Head Office-Level Violations of Fair Competition Code in FY2011: Drug Marketing Industry’s FTC
May 23, 2012
- Greater Centralization, Clarity Needed in Formulating Medical Innovation Policy: Dr Teshirogi of JPMA
May 21, 2012
- Pharma Industry FTC Implements New GL on Restriction of Business Entertaining Rules, Without Acceptance of CAA
May 21, 2012
- JPMA Approves MTPC’s Re-Enrollment 16 Months after Quitting
May 18, 2012
- “Cost-Effective Assessment Inhibits Innovation”: FPMAJ Chairman Naito
May 18, 2012
- Interview with Alfonso G. Zulueta of PhRMA
May 14, 2012
- Greater Concern than Hope about HTA: Mr Zulueta of PhRMA
May 14, 2012
- Participation in TPP to Lead to Higher NHI Prices: JMA VP Nakagawa
May 10, 2012
- 87% of Respondents Affirmative on Introduction of Medicoeconomic Assessment: JAPhMed Survey
May 9, 2012
- JPMA Compiles Manual for Providing Drugs in the Event of Disasters
April 24, 2012
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…